Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine XR vs Sertraline in Acute Bipolar Depression
NCT00857584Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2009
- Primary completion
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of quetiapine (extended-release tablet, brand name: Bipresso) in bipolar disorder (BD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Montgomery Asberg Depression Rating Scale at 2 weeks. Started May 2009; status: completed.
02
Drugs
quetiapine (extended-release tablet, brand name: Bipresso)
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT00857584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00857584.